Clinical Trials Logo

Aggressive Lymphoma clinical trials

View clinical trials related to Aggressive Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05412290 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Start date: December 22, 2022
Phase: Phase 1
Study type: Interventional

This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.

NCT ID: NCT05020678 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Start date: August 20, 2021
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

NCT ID: NCT04806035 Active, not recruiting - Follicular Lymphoma Clinical Trials

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Start date: April 23, 2021
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.

NCT ID: NCT03492125 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study Of The Selective PKC-β Inhibitor MS- 553

Start date: May 25, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT ID: NCT01686321 Completed - Aggressive Lymphoma Clinical Trials

Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma

B-R-ENDA
Start date: July 4, 2012
Phase: Phase 2
Study type: Interventional

Bendamustine is a well tolerable and very active agent in the treatment of Non Hodgkin's lymphoma. However, in particular in aggressive B-cell lymphoma, only very few, small studies have investigated the role of bendamustine in the treatment algorithm. The aim of the current B-R-ENDA trial is to investigate efficacy and toxicity of the combination treatment of bendamustine and subcutaneous rituximab in old patients or in elderly patients with high comorbidity who do not qualify for a CHOP like treatment. The results of this study will form the basis of a larger, prospective randomized phase III trial.

NCT ID: NCT01562977 Completed - Clinical trials for Mantle Cell Lymphoma

Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

RGemOx
Start date: April 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.